U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07214363) titled 'The Safety and Efficacy of Irreversible Electroporation for the Treatment of Perivascular Liver Cancers' on Oct. 01.
Brief Summary: Malignant liver tumors are among the most common cancers worldwide, with over 10,000 new cases reported annually in Taiwan. Despite the availability of various treatment options, the prognosis for primary hepatocellular carcinoma and other metastatic liver cancers remains poor, with more than 8,000 deaths each year. The majority of patients (approximately 70%-85%) are diagnosed at an advanced stage or are deemed unresectable. In contrast, patients with small tumors often have a chance of cure. According...